Pharmacological prophylaxis of venous thromboembolism in contemporary radical retropubic prostatectomy: does concomitant pelvic lymphadenectomy matter?
The prevention of venous thromboembolism is a major concern in cancer patients undergoing pelvic surgery. Radical retropubic prostatectomy is a common treatment for localized prostate cancer and has been identified as a high risk procedure for postoperative venous thromboembolism. However, most patients diagnosed with prostate cancer in the current era have clinically localized, low volume disease and the risk of venous thromboembolism is very low. Multiple guidelines exist for the prevention of venous thromboembolism in patients undergoing radical retropubic prostatectomy and pharmacological venous thromboembolism prophylaxis is recommended. Most urological surgeons in the USA however, do not routinely utilize pharmacological prophylaxis. A major concern arises when radical retropubic prostatectomy is performed with a concomitant pelvic lymphadenectomy. Pharmacological prophylaxis is known to increase the rate of lymph drainage and the rate of lymphocele formation. Evidence suggests that lymphocele may be an independent risk factor for venous thromboembolism in the postoperative period. These factors raise concern over current guidelines calling for routine use of pharmacological venous thromboembolism prophylaxis in radical retropubic prostatectomy especially when lymphadenectomy is performed simultaneously.
Jessie
Benjamin C
BC
Emory University School of Medicine, Department of Urology, Atlanta, Georgia, USA. benjamin_jessie@hotmail.com
Marshall
Fray F
FF
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D010388:Pelvis; D011468:Prostatectomy / Q000009:adverse effects*; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000517:prevention & control*
D005343:Fibrinolytic Agents